Contact Dermatitis Emerging Drugs, 2020 | DelveInsight Business Research LLP

August 28 21:06 2020
Contact Dermatitis Emerging Drugs, 2020 | DelveInsight Business Research LLP

DelveInsight Business Research LLP
Contact Dermatitis Pipeline Insight, 2020″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Contact Dermatitis market. A detailed picture of the Contact Dermatitis pipeline landscape is provided, which includes the disease overview and Contact Dermatitis treatment guidelines.

Contact Dermatitis (CD) is a type of eczema triggered by contact with a particular substance in the environment that the person is allergic to; it may react by causing the skin to itch and become red.

 

Contact Dermatitis Emerging Drugs

  1. EB01 Cream: Edesa Biotech
  2. PDC-APB: Hapten Sciences

 

The dynamics of Contact Dermatitis market is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise of efficient treatment options. The launch of emerging therapies is expected during the forecast period of 2020-2030.

EB01 is a novel sPLA2 inhibitor for the topical treatment of chronic ACD. The sPLA2 inhibitors are designed to inhibit the inflammatory process at its inception rather than after inflammation has occurred. The drug inhibits sPLA2 from degrading phospholipids to produce arachidonic acid. Arachidonic acid is processed via the LOX-COX pathway to generate several pro-inflammatory signalling molecules. The drug exerts its anti-inflammatory activity upstream of currently approved NSAIDs, which target the LOX-COX pathway. The FDA accepted Edesa’s investigational new drug (IND) application of EB01 for CD patients in November 2018. In June 2019, Edesa Biotech and Stellar Biotechnologies completed share exchange agreement. The combined company, called Edesa Biotech, thereafter, focused on the development and advancement of innovative treatments for dermatological and gastrointestinal indications. In December 2019, the company reported that EB01 had demonstrated positive safety data in healthy volunteers participating in its ongoing phase IIb clinical study in chronic ACD. Considering this positive result, the company expanded the phase IIb dermatitis study to patients with facial lesions. Currently, the drug is still being investigated in phase II clinical developmental trial in the United States for CD.

PDC-APB is a small molecule that acts like a vaccine to prevent the excruciating itching and rash (CD) caused by exposure to urushiol (yoo-ROO-she-ol) oil in poison ivy, poison oak, and poison sumac plants. Hapten licensed PDC-APB from the University of Mississippi in 2010. In 2015, the company had filed an Investigational New Drug (IND) application of PDC-APB for CD caused by poison ivy, poison oak, and poison sumac plants. The drug has already completed its phase I trial in January 2018 and in June 2019, Hapten Sciences published data regarding attainment of a fourth patent by the University of Mississippi for its investigational product that could prevent the painful itching and rash due to exposure to poison ivy, poison oak, and

Scope of the report

  • The Contact Dermatitis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Contact Dermatitis across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Contact Dermatitis therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Contact Dermatitis research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Contact Dermatitis.

 

Request for sample pages

Table of contents

1. Report Introduction

2. Contact Dermatitis 

2.1. Overview

2.2. History 

2.3. Contact Dermatitis Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Contact Dermatitis Diagnosis 

2.6.1. Diagnostic Guidelines

3. Contact Dermatitis Current Treatment Patterns

3.1. Contact Dermatitis Treatment Guidelines

4. Contact Dermatitis – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Contact Dermatitis companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Contact Dermatitis Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Contact Dermatitis Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Contact Dermatitis Late Stage Products (Phase-III)

7. Contact Dermatitis Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Contact Dermatitis Discontinued Products

13. Contact Dermatitis Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition 

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

Detailed information in the report? 

14. Contact Dermatitis Key Companies

15. Contact Dermatitis Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Contact Dermatitis Unmet Needs

18. Contact Dermatitis Future Perspectives

19. Contact Dermatitis Analyst Review  

20. Appendix

21. Report Methodology

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

view more articles

About Article Author